Treatment of extraintestinal manifestations in inflammatory bowel disease

被引:2
作者
Adrian A. van Bodegraven
A. Salvador Peña
机构
[1] Free University Medical Center,Department of Gastroenterology
关键词
Bone Mineral Density; Inflammatory Bowel Disease; Infliximab; Tacrolimus; Alendronate;
D O I
10.1007/s11938-003-0002-0
中图分类号
学科分类号
摘要
Extraintestinal manifestations (EIM) of inflammatory bowel disease (IBD) occur rather frequently and may be found in up to 30% of patients. However, surprisingly few randomized, controlled studies have been conducted that were specifically aimed at the treatment of EIM of IBD patients. Therefore, most therapies of EIM are empiric or deduced from studies in populations with other type of patients. EIM may be associated with active IBD. Treatment of active IBD is, therefore, the mainstay of treatment of EIM. Lifestyle modification as a means of therapy is a recent subject of study in chronic conditions, such as IBD. Based on epidemiologic and experimental findings, EIM of various tracts can be modified by optimizing alimentary intake, refraining from sedentary lifestyle, and adapting smoking habits. Not many new drugs for treatment of EIM have been developed during the past few years; the role of infliximab has been extended in particular in Crohn’s disease-related EIM. Careful consideration of prescribed drugs remains necessary due to potential interaction with the course of IBD.
引用
收藏
页码:201 / 212
页数:11
相关论文
共 169 条
[41]  
Mitchell JA(2002)Cutaneous manifestations of inflammatory bowel disease improve with infliximab therapy [abstract] Gastroenterology 122 A618-A618
[42]  
Fairclough PD(2002)Successful treatment of IBD-associated pyoderma gangrenosum with infliximab [abstract] Gastroenterology 122 A168-A168
[43]  
Cipolla G(2001)Hemostatic imbalance in active and quiescent ulcerative colitis Am J Gastroenterol 96 487-493
[44]  
Crema F(2003)Low vitamin B(6) plasma levels, a risk factor for thrombosis, in inflammatory bowel disease: role of inflammation and correlation with acute phase reactants Am J Gastroenterol 98 112-117
[45]  
Sacco S(1998)High prevalence of hyperchomocysteinemia in patients with inflammatory bowel disease: a pathogenic link with thromboembolic complications? Thromb Haemost 80 542-545
[46]  
Braun J(2000)Homocysteine in inflammatory bowel disease: a risk factor for thromboembolic complications? Am J Gastroenterol 95 2825-2830
[47]  
Sieper J(2001)Extraintestinal complications of inflammatory bowel disease Curr Treat Option Gastroenterol 4 227-243
[48]  
van der Horst-Bruinsma IE(2002)Sulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines Gut 51 536-539
[49]  
Clegg DO(2000)Infliximab and methotrexate in the treatment of rheumatoid arthritis N Engl J Med 434 1594-1602
[50]  
Dijkmans BA(1999)Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs JAMA 282 1929-1933